DiamiR Announces Poster Presentation at the Clinical Trials on Alzheimer's Disease 2014

MONMOUTH JUNCTION, NJ--(Marketwired - November 17, 2014) - DiamiR Biosciences, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the company's Chief Executive Officer, Dr. Kira Sheinerman, will participate in the 7^th annual Clinical Trials on Alzheimer's Disease in Philadelphia, PA and will present data on analysis of circulating brain-enriched microRNAs for detection and differentiation of Mild Cognitive Impairment, Alzheimer's and Parkinson's diseases.

Title: Potential of circulating brain-enriched microRNAs as biomarkers for selection, stratification and monitoring of patients in clinical trials
Session / Date: Friday, November 21
Poster #: P2.30
Location: Loews Philadelphia Hotel

About DiamiR Biosciences

DiamiR is a privately held molecular diagnostics company focused on developing noninvasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer's disease, Parkinson's disease, and other conditions. The proprietary technology is based on quantitative analysis of organ-enriched microRNA signatures in plasma and can be used for screening, patient stratification as well as disease and treatment monitoring. For more information, please visit the company's website at www.diamirbio.com.

Please Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; the results of studies of our product candidates conducted by others; our ability to obtain future funding on acceptable terms; our ability to obtain regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights; and innovation by our competitors.